Nils Johnson
Associate Professor of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Background Assessing the myocardial mass at risk is essential in evaluating patients with coronary artery disease. This study aims to establish reference values for vessel‐specific myocardial mass derived from coronary computed tomography angiography, providing a quantitative assessment of the myocardial mass subtended by each epicardial vessel. Methods Left ventricular (LV) and vessel‐specific myocardial mass were calculated from coronary computed tomography angiography using the Voronoi method in patients with stable coronary artery disease. Myocardial mass was quantified for each epicardial coronary artery with a diameter >1.5 mm. Results We included 948 patients with 9228 epicardial coronary artery branches. Mean age was 66±9 years. The cohort was predominantly male (77%); 66% had hypertension, and 22% had diabetes. Vessel‐specific myocardial mass was calculated for 2767 main epicardial arteries (948 left anterior descending, 948 left circumflex, and 871 right coronary artery) and 6461 side branches (1888 diagonals, 1208 septals, 1422 obtuse marginals, 247 ramus intermedius, 850 right posterior descending, and 846 posterolateral branches). Median LV mass was 141 grams (interquartile range 118–166); women had smaller LV mass than men (106 [93–123] grams versus 150 [132–173] grams, P <0.001). On average, the left anterior descending subtended 42.5% [37.9–48.1] of LV mass, the left circumflex artery 28.8% [21.9–5.7], and the right coronary artery 26.4% [20.9–31.9]. Median LV mass subtended by the first septal, first diagonal, and first obtuse marginal were 8.9% [6.4–11.1], 7.9% [4.52–2.0], and 10.2% [4.52–12.0], respectively. Conclusions This study quantified the myocardial mass subtended by each major artery in the coronary circulation. Understanding the vessel‐specific mass at risk has significant clinical implications for personalizing revascularization strategies. Registration This is a retrospective analysis of 5 prospectively conducted trials (P3: NCT03782688; P4: NCT05253677; PPG Global: NCT04789317; Euro‐CRAFT: NCT05805462; INSIGHTFUL‐FFR: NCT05437900). No additional registration was required.
Year:
2025
Background and Aims The randomized CENTURY trial tested the hypothesis that a comprehensive strategy integrating intense lifestyle modification and aggressive medical management to goals with revascularization reserved for severely reduced coronary flow capacity (CFC) by positron emission tomography (PET) would reduce risk factors, subsequent revascularization, death and myocardial infarction (MI) compared with standard of care in chronic stable coronary artery disease (CAD). Methods Participants were randomly assigned to standard or comprehensive care groups. Rest-stress PET quantified CFC for physiological CAD severity at baseline, 2, 5, and up to 11 years. The comprehensive care group reviewed PET results with frequent clinic visits and open 24/7 phone/email support. Standard care lacked supportive contact with blinded PET results that were unblinded only for severely reduced CFC with high mortality risk for potential revascularization. Results Between 2009–2017, 515 patients were assigned to comprehensive care and 513 to standard care and followed for 5 or more years. Comprehensive vs standard care decreased risk factors and summed 5-year risk score (Δ−1.1 vs + 0.33; 95% confidence interval −1.84 to −0.97; P < .0001), decreased cumulative 11-year all-cause death (4.7% vs 8.2%; P = .023), death or MI (7.0% vs 11.1%; P = .024) late revascularization (9.5% vs 14.8%; P = .021) and major adverse cardiac events (20.5% vs 29.9%; P = .0006). Only 56 of 1028 (5.4%) CENTURY patients with chronic CAD had revascularization within 90 days predominantly guided by CFC severity. Conclusions The randomized CENTURY trial demonstrates that comprehensive integrated lifestyle modification and medical management towards goals with revascularization reserved for severely reduced CFC, significantly reduced risk factor scores, death, death or MI, and revascularization. ClinicalTrials.gov NCT00756379
Year:
2025
Aims The haemodynamic physiology of the aortic valve has attracted renewed attention after the introduction of transcatheter aortic valve implantation (TAVI). Understanding normal valve function, especially under stress conditions, permits identification of early pathology and quantification of the extent to which TAVI restores normalcy. We aimed to describe the haemodynamic behaviour of a normal aortic valve during stress via invasive, non-invasive, and computational techniques. Methods and results Our cohort included subjects already undergoing invasive coronary angiography for clinical indications. Haemodynamic measurements were made invasively and non-invasively along with dobutamine infusion. Additionally, patient-specific anatomy from computed tomographic imaging served as input to a computational fluid dynamics model using fluid–structure interaction analysis. We studied 10 subjects with simultaneous invasive sensors and non-invasive echocardiography during dobutamine administration. The majority of normal valves (7 of 10) demonstrated a fall in the invasive gradient during stress, in contrast to the increase noted by Doppler assessment. The stress aortic valve index, a relative measure of pressure loss over the valve during ejection, uniformly exceeded 0.90 with median value of 0.96 and interquartile range 0.94–1.00. Simulation of increased transvalvular flow via faster heart rates produced a highly linear relationship (coefficient of determination R2 equal to 0.95) with the mean transvalvular pressure gradient. Conclusion Normal aortic valves demonstrated minimal pressure loss even during the high transvalvular flow generated by dobutamine infusion. Computational simulation using anatomy from a normal aortic valve behaved like a resistor, since mean gradient scaled directly with transvalvular flow.
Year:
2025
Background Due to aging of the population, the prevalence of aortic valve stenosis will increase drastically in upcoming years. Consequently, transcatheter aortic valve implantation (TAVI) procedures will also expand worldwide. Optimal selection of patients who benefit with improved symptoms and prognoses is key, since TAVI is not without its risks. Currently, we are not able to adequately predict functional outcomes after TAVI. Quality of life measurement tools and traditional functional assessment tests do not always agree and can depend on factors unrelated to heart disease. Activity tracking using wearable devices might provide a more comprehensive assessment. Objective This study aimed to identify objective parameters (eg, change in heart rate) associated with improvement after TAVI for severe aortic stenosis from a wearable device. Methods In total, 100 patients undergoing routine TAVI wore a Philips Health Watch device for 1 week before and after the procedure. Watch data were analyzed offline—before TAVI for 97 patients and after TAVI for 75 patients. Results Parameters such as the total number of steps and activity time did not change, in contrast to improvements in the 6-minute walking test (6MWT) and physical limitation domain of the transformed WHOQOL-BREF questionnaire. Conclusions These findings, in an older TAVI population, show that watch-based parameters, such as the number of steps, do not change after TAVI, unlike traditional 6MWT and QoL assessments. Basic wearable device parameters might be less appropriate for measuring treatment effects from TAVI.
Year:
2024
Collaborators (16)
Jagat Narula
-
Hiromasa Otake
Kobe University Graduate School of Medicine
Ruosha Li
Professor
The University of Texas Health Science Center at Houston
Bon-Kwon Koo
Seoul National University Hospital
Toshiro Shinke
Professor
Showa University School of Medicine
Thomas Engstrøm
Rigshospitalet
Salvatore Brugaletta
idibaps
Bjarne L. Nørgaard
-
C Berry
Personal Chair in Cardiology and Imaging
University of Glasgow
James Spratt
Professor in Interventional Cardiology
St George’s, University of London
Gianluca Campo
Full professor, Interventional Cardiologist
Azienda Ospedaliero Universitaria di Ferrara Arcispedale Sant'Anna
Lokien X. van Nunen
Catharina Ziekenhuis
Giulio Stefanini
Humanitas University
Divaka Perera
King’s College London
Evald Høj Christiansen
-
Emanuele Barbato
Docenti di ruolo di Ia fascia
Sapienza University of Rome
Make your next move.
Prepare your application
Review drafts before you send them.